



# gritstone

ONCOLOGY

## Gritstone Oncology to Webcast Presentations from Two Upcoming Investor Conferences in September

September 8, 2020

EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- [Gritstone Oncology, Inc.](https://www.gritstoneoncology.com) (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, president and chief executive officer, will present a webcasted company overview at two upcoming investor conferences in September.

- H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 10:30 a.m. ET
- Cantor Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 9:20 a.m. ET

A live webcast will be available within the Investors & Media section of the Gritstone Oncology website at <https://ir.gritstoneoncology.com/investors/events>. An archived replay will be accessible for 30 days following the event.

### About Gritstone Oncology

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of cancer immunotherapies to fight multiple cancer types. Gritstone develops its products by leveraging two key pillars—second, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict, from a routine tumor biopsy, the tumor-specific neoantigens (TSNA) that are presented on a patient's tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients' TSNA to potentially drive the patient's immune system to specifically attack and destroy tumors. The company's individualized neoantigen-based immunotherapy, GRANITE, and its "off the shelf" shared neoantigen-based immunotherapy, SLATE, are being evaluated in clinical studies. Novel tumor-specific antigens can also provide targets for bispecific antibody (BiSAb) therapeutics for solid tumors, and Gritstone's BiSAb program is currently in lead optimization. For more information, please visit [gritstoneoncology.com](https://www.gritstoneoncology.com).

### Contacts

Media:

Dan Budwick

1AB

(973) 271-6085

[dan@1abmedia.com](mailto:dan@1abmedia.com)

Investors:

Alexandra Santos

Wheelhouse Life Science Advisors

(510) 871-6161

[asantos@wheelhousesa.com](mailto:asantos@wheelhousesa.com)



Source: Gritstone Oncology, Inc